U.S. DNA-Based Diagnostic Test and Equipment Market Analysis & Directions

Table of Contents

Introduction

Section A: Market Condition

1. Market Overview

• 1.1 Market History
  • Table 1-1 Important Industry Developments
• 1.2 Market Structure and Character
  • 1.2.1 U.S. Regulatory Structure
  • 1.2.2 Regulatory Update
• 1.3 Major Players and Character
  • Table 1-2 Market Participants and Their Multiple Business Models
• 1.4 Major Players' Products (Product Name, Targeted Diagnostic, Price, Product Feature)

2. Market Trends, 2008-2010

• 2.1 Market Size and Forecast: Test Products & Equipment Markets
  • Table 2-1 Revenue by 15 Surveyed Companies, 2008-2010
  • Table 2-2 Maker (15) Share, 2008-2010
  • Table 2-3 Estimates of Current U.S. Market Size
• 2.2 Equipment & Test Product Market Trends
  • Table 2-4 Equipment Market Forecast, by Product Type, 2008-2010
  • Table 2-5 Test Product Market Size, by Test Product Segment
  • Table 2-6 Diagnostic Testing Product Segments
  • Table 2-7 Market Size Human Gene Tests, by Type of Test

3. Market Share by Product Segment of Surveyed Companies

• 3.1Market Share Overview 2008 vs. 2010
  • Table 3-1 Market Share Overview 2008 vs. 2010
• 3.2 Maker Shares, by Type of Test Product
  • 3.2.1Blood Screens
  • Table 3-2 Maker Share
  • 3.2.2 Infectious Diseases (Viral)
  • Table 3-3 Maker Share
  • 3.2.3 Infectious Diseases (Bacterial)
  • Table 3-4 Maker Share
  • 3.2.4 Human Gene Tests
  • Table 3-5 Maker Share
• 3.3 Maker Share, by Equipment
  • 3.3.1 RT-PCR
  • Table 3-6 Maker Share
  • 3.3.2 DNA Amplification and Detection
  • Table 3-7 Maker Share
  • 3.3.3 Microarrays
  • Table 3-8 Maker Share

4. Distribution Structure

• 4.1 Basic Distribution Pattern
  • 4.1.1 The Customer Continuum
  • 4.1.2 Direct Sales to Clinical Labs - Genetic Tests as "Medical Devices"
  • 4.1.3 Direct Sales to Physicians - Genetic Tests as "Laboratory Service"
• 4.2 Sales (%) by Channel
• 4.3 Sales Agent Intervention and Influence
  • 4.3.1 Physician Customers
  • 4.3.2 Laboratory Customers
  • 4.3.3 Clinical Labs as Distribution Partners
• 4.4 Distribution Character in B-to-C Business

5. New Product Development Trends

• 5.1 Development Trends by Product Segment
• 5.2 Hot New Products

6. Technology Character in DNA Diagnostic Product Development

• 6.1 Trends of Development/Supported Technology
  • 6.1.1 Multiplex Testing and Genomic Hybridization
  • 6.1.2 Multiplexed (Multi-Analyte) Platforms
  • 6.1.3 More Choices in Gene Amplification
• 6.2 Development Speed and Improvement Points in Sequencing Technology
  • Table 6-1 Comparison of Faster (Ultrahigh-Throughput) DNA Sequencers: Commercially Available Systems
  • Table 6-2 New Sequencing Platforms Under Development

7. Future of Market

• 7.1 Market Potentiality and Roadmap
  • Table 7-1 Market Positioning 2010 to 2012: Major Categories of Test Products
  • Table 7-2 Market Positioning 2010 to 2012: DNA-based Diagnostic Tests & Key Equipment
• 7.2. Roadmap: Development and Drivers, 2009, 2010/11, Beyond 2012

8. Issues and Strategy for the DNA-Based Diagnostic and Test Business

• 8.1 Management of Individual Information (Privacy)
• 8.2 Organization of Ethics Committee, etc.
• 8.3 Current Status of DNA Counseling
• 8.4 Policy and Proposal by Insurance Industry

Section B: Company Case Studies (15 Companies)

Common research Item

• 1) Company In-Brief
  • Revenue
  • Location
  • Established Year
  • Special Note
• 2) Revenue by Business Segment (DNA-based Diagnostics and Tests, Drugs, Medical Equipment, etc.)
• 3) Product Revenue Forecasts, 2007-2009
  • Equipment Revenue
  • Product Revenue, by Segment
• 4) Most Important Product for Sales and Marketing Spending - and Key Reason for Spending on Product
• 5) Distribution Policy
  • Basic Distribution Flow
  • Status of Usage of Sales Agents, Wholesalers, etc.
• 6) R&D Activity
  • Expenditure
  • Most Important R&D Area for Capital Spending - and Key Reason for Spending
• 7) Technology Trends
  • Technology Used in DNA-based Diagnostic and Test
  • Patents Status
• 8) New Product Development Activity
  • Product Character
  • Product Development Areas where Company Invests More Money and People Resources
• 9) Profitability
  • Revenue Contribution of DNA-based Diagnostic and Test Business
  • Profitability (%) of the Above-mentioned Business
• 10) Business Policies
  • Management of Privacy
  • Company Policy on Ethics
  • Status of Usage of DNA Counseling
• 11) Market Trends (Roadmap): Future DNA Diagnostic and Test Market Outlook
  • Product Segment where Company Can Expect Brighter Future
  • Market Expansion and Obstruction Factors
  • Business Potentiality of B-to-C Segment

• 1. Abbott Molecular Diagnostics
• 2. Becton Dickinson (BD) Diagnostics
• 3. BioMerieux USA/BioTheranostics
• 4. Celera Corp.
• 5. Decode Genetics
• 6. Qiagen North America/Digene
• 7. Genomic Health
• 8. Gen-Probe
• 9. Interleukin Genetics
• 10. Life Technologies (formerly Applied Biosystems & Invitrogen)
• 11. Myriad Genetics
• 12. Novartis V&D
• 13. Roche (Molecular Diagnostics & Applied Science divisions)
• 14. Siemens Healthcare Diagnostics (formerly Bayer Diagnostics)
• 15. Hologic Molecular (formerly Third Wave Technologies)

Section C: Additional Companies in DNA-based Diagnostics, by Market Segment

Common Research Item

• Location/Contact Information
• URL
• Private or Public
• Revenue
• Current Product or
• Developing Product & Application
• Technology, R&D and Commercialization
• Strategic Alliance and Partner

• 1. Consumer Genomics
  • 1.1 ~ 1.5 Total 5 Companies
• 2. DNA-Based Test Makers
  • 2.1 ~ 2.8 Total 8 Companies
• 3. Instrumentation and Tools
  • 3.1 ~3.14 Total 14 Companies